Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Andrew T. Tenaglia, BA

Articles by Andrew T. Tenaglia, BA

Concomitant Medical Conditions and Total Cost of Care in Patients With Migraine: A Real-World Claims Analysis

ByMichael Polson, PharmD, MS,Ted D. Williams, PharmD, BCPS,Lindsay C. Speicher, JD,Mkaya Mwamburi, MD, PhD, MA,Peter S. Staats, MD, MBA,Andrew T. Tenaglia, BA

February 18th 2020

Real-World Assessment of Concomitant Opioid Utilization and Associated Trends in Patients With Migraine

ByAnne Kangethe, PharmD, PhD, RPh, MPH,Michael Polson, PharmD, MS,Themmi M. Evangelatos, PharmD, MSBA,Lindsay C. Speicher, JD,Andrew T. Tenaglia, BA,Peter S. Staats, MD, MBA,Eric J. Liebler,Mkaya Mwamburi, MD, PhD, MA

February 18th 2020

Review of Evidence on Noninvasive Vagus Nerve Stimulation for Treatment of Migraine: Efficacy, Safety, and Implications

ByMkaya Mwamburi, MD, PhD,Andrew T. Tenaglia, BA,Eric J. Leibler,Peter S. Staats, MD, MBA

December 13th 2018

Noninvasive Vagus Nerve Stimulation in a Primary Care Setting: Effects on Quality of Life and Utilization Measures in Multimorbidity Patients With or Without Primary Headache

ByIain Strickland, PhD, BSc,Mkaya Mwamburi, MD, PhD,Steven Davis BSc,James C.R. Ward, MBBS,Janet Day, MBChB,Andrew T. Tenaglia, BA,Eric J. Leibler,Peter S. Staats, MD, MBA

December 13th 2018

Cost-effectiveness of Noninvasive Vagus Nerve Stimulation for Acute Treatment of Episodic Migraine and Role in Treatment Sequence Strategies

ByMkaya Mwamburi, MD, PhD,Andrew T. Tenaglia, BA,Eric J. Leibler,Peter S. Staats, MD, MBA

December 13th 2018

Review of Non-Invasive Vagus Nerve Stimulation (gammaCore): Efficacy, Safety, Potential Impact on Comorbidities, and Economic Burden for Episodic and Chronic Cluster Headache

ByMkaya Mwamburi, MD, PhD (HEOR), MA (Econ),Eric J. Liebler, BA,Andrew T. Tenaglia, BA

November 16th 2017

Latest Updated Articles

Review of Non-Invasive Vagus Nerve Stimulation (gammaCore): Efficacy, Safety, Potential Impact on Comorbidities, and Economic Burden for Episodic and Chronic Cluster Headache
Published: November 16th 2017 | Updated:
Review of Evidence on Noninvasive Vagus Nerve Stimulation for Treatment of Migraine: Efficacy, Safety, and Implications
Published: December 13th 2018 | Updated:
Noninvasive Vagus Nerve Stimulation in a Primary Care Setting: Effects on Quality of Life and Utilization Measures in Multimorbidity Patients With or Without Primary Headache
Published: December 13th 2018 | Updated:
Cost-effectiveness of Noninvasive Vagus Nerve Stimulation for Acute Treatment of Episodic Migraine and Role in Treatment Sequence Strategies
Published: December 13th 2018 | Updated:
Concomitant Medical Conditions and Total Cost of Care in Patients With Migraine: A Real-World Claims Analysis
Published: February 18th 2020 | Updated:
Real-World Assessment of Concomitant Opioid Utilization and Associated Trends in Patients With Migraine
Published: February 18th 2020 | Updated:

Trending on AJMC

White House, Pfizer Reach Agreement on Drug Discounts; Trump Announces TrumpRx

Predicting Patient Response in the Move Toward Precision Medicine in Myasthenia Gravis

FDA Approves Remibrutinib for Chronic Spontaneous Urticaria

Striking the Balance Between Cutting-Edge Oncology Care, Affordability: Brian Mulherin, MD

AI Seen as Key to Reducing Health Care Claim Denials, Survey Finds

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

© 2025 MJH Life Sciences^®

All rights reserved.